<DOC>
	<DOCNO>NCT00809783</DOCNO>
	<brief_summary>Safety extension study Phase 3 Osteoarthritis trial Tanezumab</brief_summary>
	<brief_title>Extension Study Of Tanezumab In Osteoarthritis</brief_title>
	<detailed_description>This study terminate 27 October 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Must participate previous ( specific ) Phase 3 trial Tanezumab osteoarthritis Willing comply schedule visit treatment plan Is medically fit participate trial judgement Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Tanezumab OA arthritis</keyword>
</DOC>